Kierkus Jaroslaw,Pesegova Marina,Klopocka Maria,Brankovic Marija S,Kasai Noriyuki,Efuni Sergey,Kong Jennifer,Nakajima Yu,Jordan Christina,Matsui Takeshi,Feagan Brian G,Strout Vincent (2020) Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis, CROHNS & COLITIS 360, vol. 2, br. 3, str. - (Article) 

Reinisch Walter,Gibson Peter R,Sandborn William J,Feagan Brian G,Strauss Richard S,Johanns Jewel,Padgett Lakshmi,Adedokun Omoniyi J,Colombel Jean-Frederic,Collins Judith,Rutgeerts Paul,Tarabar Dino K,Marano Colleen W (2018) Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension, JOURNAL OF CROHNS & COLITIS, vol. 12, br. 9, str. 1053-1066 (Article) 

Gibson Peter R,Feagan Brian G,Sandborn William J,Marano Colleen W,Strauss Richard S,Johanns Jewel,Padgett Lakshmi,Collins Judith,Tarabar Dino K,Hebzda Zbigniew,Rutgeerts Paul,Reinisch Walter (2016) Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, vol. 7, br. , str. - (Article) 

Sandborn William J,Regula Jaroslaw,Feagan Brian G,Belousova Elena,Jojic Njegica Z,Lukas Milan,Yacyshyn Bruce,Krzeski Piotr,Yeh Chyon-Hwa,Messer Christi A,Hanauer Stephen B (2009) Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis, GASTROENTEROLOGY, vol. 137, br. 6, str. 1934-1943 (Article)